Literature DB >> 22665271

Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes.

Karelle Ménochet1, Kathryn E Kenworthy, J Brian Houston, Aleksandra Galetin.   

Abstract

Interindividual variability in activity of uptake transporters is evident in vivo, yet limited data exist in vitro, confounding in vitro-in vivo extrapolation. The uptake kinetics of seven organic anion-transporting polypeptide substrates was investigated over a concentration range in plated cryopreserved human hepatocytes. Active uptake clearance (CL(active, u)), bidirectional passive diffusion (P(diff)), intracellular binding, and metabolism were estimated for bosentan, pitavastatin, pravastatin, repaglinide, rosuvastatin, telmisartan, and valsartan in HU4122 donor using a mechanistic two-compartment model in Matlab. Full uptake kinetics of rosuvastatin and repaglinide were also characterized in two additional donors, whereas for the remaining drugs CL(active, u) was estimated at a single concentration. The unbound affinity constant (K(m, u)) and P(diff) values were consistent across donors, whereas V(max) was on average up to 2.8-fold greater in donor HU4122. Consistency in K(m, u) values allowed extrapolation of single concentration uptake activity data and assessment of interindividual variability in CL(active) across donors. The maximal contribution of active transport to total uptake differed among donors, for example, 85 to 96% and 68 to 87% for rosuvastatin and repaglinide, respectively; however, in all cases the active process was the major contributor. In vitro-in vivo extrapolation indicated a general underprediction of hepatic intrinsic clearance, an average empirical scaling factor of 17.1 was estimated on the basis of seven drugs investigated in three hepatocyte donors, and donor-specific differences in empirical factors are discussed. Uptake K(m, u) and CL(active, u) were on average 4.3- and 7.1-fold lower in human hepatocytes compared with our previously published rat data. A strategy for the use of rat uptake data to facilitate the experimental design in human hepatocytes is discussed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22665271      PMCID: PMC3422540          DOI: 10.1124/dmd.112.046193

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  52 in total

1.  Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.

Authors:  Mikko Niemi; Janne T Backman; Lauri I Kajosaari; Julian B Leathart; Mikko Neuvonen; Ann K Daly; Michel Eichelbaum; Kari T Kivistö; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2005-06       Impact factor: 6.875

2.  Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches.

Authors:  Kiyomi Ito; J Brian Houston
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

3.  Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations.

Authors:  E M Landaw; J J DiStefano
Journal:  Am J Physiol       Date:  1984-05

4.  Cyclosporine markedly raises the plasma concentrations of repaglinide.

Authors:  Lauri I Kajosaari; Mikko Niemi; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen; Janne T Backman
Journal:  Clin Pharmacol Ther       Date:  2005-10       Impact factor: 6.875

5.  Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

Authors:  Richard H Ho; Rommel G Tirona; Brenda F Leake; Hartmut Glaeser; Wooin Lee; Christopher J Lemke; Yi Wang; Richard B Kim
Journal:  Gastroenterology       Date:  2006-03-06       Impact factor: 22.682

6.  Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance.

Authors:  Hayley S Brown; Michael Griffin; J Brian Houston
Journal:  Drug Metab Dispos       Date:  2006-11-28       Impact factor: 3.922

Review 7.  Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.

Authors:  Yoshihisa Shitara; Yuichi Sugiyama
Journal:  Pharmacol Ther       Date:  2006-05-22       Impact factor: 12.310

Review 8.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction.

Authors:  Marcella Martignoni; Geny M M Groothuis; Ruben de Kanter
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-12       Impact factor: 4.481

9.  Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans.

Authors:  Naoki Ishiguro; Kazuya Maeda; Wataru Kishimoto; Asami Saito; Akiko Harada; Thomas Ebner; Willy Roth; Takashi Igarashi; Yuichi Sugiyama
Journal:  Drug Metab Dispos       Date:  2006-04-12       Impact factor: 3.922

10.  In vivo inhibition of oxidative drug metabolism by, and acute toxicity of, 1-aminobenzotriazole (ABT). A tool for biochemical toxicology.

Authors:  B A Mico; D A Federowicz; M G Ripple; W Kerns
Journal:  Biochem Pharmacol       Date:  1988-07-01       Impact factor: 5.858

View more
  33 in total

1.  Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Authors:  Manthena V Varma; Stefanus J Steyn; Charlotte Allerton; Ayman F El-Kattan
Journal:  Pharm Res       Date:  2015-07-09       Impact factor: 4.200

Review 2.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

3.  Optimization and Application of a Biotinylation Method for Quantification of Plasma Membrane Expression of Transporters in Cells.

Authors:  Vineet Kumar; Tot Bui Nguyen; Beáta Tóth; Viktoria Juhasz; Jashvant D Unadkat
Journal:  AAPS J       Date:  2017-07-24       Impact factor: 4.009

4.  Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes.

Authors:  Yi-An Bi; Renato J Scialis; Sarah Lazzaro; Sumathy Mathialagan; Emi Kimoto; Julie Keefer; Hui Zhang; Anna M Vildhede; Chester Costales; A David Rodrigues; Larry M Tremaine; Manthena V S Varma
Journal:  AAPS J       Date:  2017-02-10       Impact factor: 4.009

Review 5.  Drug-drug interaction studies: regulatory guidance and an industry perspective.

Authors:  Thomayant Prueksaritanont; Xiaoyan Chu; Christopher Gibson; Donghui Cui; Ka Lai Yee; Jeanine Ballard; Tamara Cabalu; Jerome Hochman
Journal:  AAPS J       Date:  2013-03-30       Impact factor: 4.009

Review 6.  The role of transporters in toxicity and disease.

Authors:  John D Schuetz; Peter W Swaan; Donald J Tweedie
Journal:  Drug Metab Dispos       Date:  2014-04       Impact factor: 3.922

7.  Permeability comparison between hepatocyte and low efflux MDCKII cell monolayer.

Authors:  Rui Li; Yi-An Bi; Yurong Lai; Kiyohiko Sugano; Stefanus J Steyn; Patrick E Trapa; Li Di
Journal:  AAPS J       Date:  2014-05-23       Impact factor: 4.009

8.  A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats.

Authors:  Priyanka Kulkarni; Ken Korzekwa; Swati Nagar
Journal:  Xenobiotica       Date:  2019-10-01       Impact factor: 1.908

Review 9.  Intracellular drug concentrations and transporters: measurement, modeling, and implications for the liver.

Authors:  X Chu; K Korzekwa; R Elsby; K Fenner; A Galetin; Y Lai; P Matsson; A Moss; S Nagar; G R Rosania; J P F Bai; J W Polli; Y Sugiyama; K L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2013-04-10       Impact factor: 6.875

Review 10.  ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans.

Authors:  M J Zamek-Gliszczynski; C A Lee; A Poirier; J Bentz; X Chu; H Ellens; T Ishikawa; M Jamei; J C Kalvass; S Nagar; K S Pang; K Korzekwa; P W Swaan; M E Taub; P Zhao; A Galetin
Journal:  Clin Pharmacol Ther       Date:  2013-02-25       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.